Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥28,835 | ¥12,766 | ¥15,569 | ¥17,712 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | ¥7,616 | ¥3,102 | ¥926 | ¥933 |
| Gross Profit | ¥21,219 | ¥9,664 | ¥14,643 | ¥16,779 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | ¥11,816 | ¥10,075 | ¥7,454 | ¥5,931 |
| G&A Expenses | ¥16,015 | ¥9,965 | ¥4,377 | ¥3,940 |
| SG&A Expenses | ¥16,015 | ¥9,965 | ¥4,377 | ¥3,940 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥1,189 | -¥850 | -¥624 | ¥3,133 |
| Operating Expenses | ¥26,642 | ¥19,190 | ¥11,207 | ¥13,004 |
| Operating Income | -¥5,423 | -¥9,526 | ¥2,812 | ¥6,908 |
| % Margin | -18.8% | -74.6% | 18.1% | 39% |
| Other Income/Exp. Net | ¥761 | -¥1,154 | -¥1,734 | -¥6,475 |
| Pre-Tax Income | -¥4,662 | -¥10,680 | ¥1,078 | ¥433 |
| Tax Expense | ¥176 | -¥3,487 | ¥696 | -¥584 |
| Net Income | -¥4,838 | -¥7,193 | ¥382 | ¥1,017 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.92 | -87.17 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.6% | -62.7% | – |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 90 | 83 | 82 | 81 |
| Weighted Avg Shares Out Dil | 90 | 83 | 83 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1,544 | ¥1,341 | ¥663 | ¥199 |
| Interest Expense | ¥783 | ¥2,495 | ¥756 | ¥3,797 |
| Depreciation & Amortization | ¥3,984 | ¥2,478 | ¥1,345 | ¥1,278 |
| EBITDA | ¥105 | -¥5,707 | ¥3,567 | ¥2,189 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |